NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DK-17-013 from the NIH Guide for Grants and Contracts
Notice of Change to Key Dates in PA-16-372 "Small Grants on Primary Immunodeficiency Diseases (R03)"
Notice NOT-AI-17-030 from the NIH Guide for Grants and Contracts
Notice NOT-MH-17-031 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-18-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic research to elucidate the impact of microenvironment, which includes cellular components of the niche, extracellular matrix, and soluble factors, on lung progenitor cell phenotype and function during development, homeostasis, repair and regeneration. Multi-disciplinary teams with complementary expertise are encouraged to propose innovative, hypothesis-based studies to catalyze this understudied area critical to advancing lung stem cell biology. This FOA will also support the development of novel 3-dimensional, multi-component models to interrogate lung stem cell niches.
Notice NOT-HL-17-519 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-068 from the NIH Guide for Grants and Contracts
Notice NOT-AA-17-006 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-316 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages grant applications for national Biomedical Technology Research Resources (BTRR). These Resources conduct research and development of new or improved technologies driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Resources technologies and experimental results. Resources should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. New applicants are strongly encouraged to submit a pre-application in response to PAR-17-315 The pre-application process provides feedback on whether the proposed technology development is appropriate for the NIGMS BTRR program, and the potential competitiveness of a full application.
Funding Opportunity PAR-17-315 from the NIH Guide for Grants and Contracts. This announcement encourages pre-applications for the creation of national Biomedical Technology Research Resources (BTRRs). These Resources develop new or improved technology driven by the needs of basic, translational, and clinical researchers. The BTRRs are charged to make their technologies available to the biomedical research community, to train members of this community in the use of the technologies, and to disseminate both the technologies and the Resources experimental results broadly.
Funding Opportunity PAR-17-313 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages exploratory/developmental research grant applications, proposing the development of innovative, collaborative research projects on brain and other nervous system function and disorders throughout life, relevant to low- and middle-income countries (LMICs). Research on neurological, mental, behavioral, alcohol and substance use disorders may span the full range of science from basic to implementation research. Scientists in the United States (U.S.) or upper-middle income countries (UMICs) are eligible to partner with scientists in LMIC institutions. Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories used are as defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
Funding Opportunity PAR-17-314 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages grant applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups.
Notice NOT-AI-17-029 from the NIH Guide for Grants and Contracts
Funding Opportunity PAS-17-311 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to fill gaps in our understanding of (a) the impact of substance abuse on HIV, HIV/HCV co-infection associated disease progression, (b) the pathogenic interactions between HIV and hepatitis C virus, (c) hepatic and non-hepatic co-morbidities associated with HIV/HCV-co-infections in people with substance abuse disorders (SUDs), and (d) the effectiveness of interferon-free direct acting antiviral (DAAs) drug regimens to treat HIV/HCV co-infections in people with SUDs. This FOA is informed by priority area in the NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html and the HHS National Viral Hepatitis Action Plan 2017-2020: https://www.hhs.gov/hepatitis/blog/2017/01/19/updated-national-viral-hepatitis-action-plan-2017-2020.html
Funding Opportunity RFA-FD-18-002 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to support the implementation of NEST through operations of the NEST CC toward sustainable operations for the future to coincide with the stated purposes and goals listed in Section IV.H of the draft Medical Device User Fee Act Performance Goals and Procedures, Fiscal Years 2018 Through 2022 letter (MDUFA IV Commitment Letter, Available at https://www.fda.gov/downloads/ForIndustry/UserFees/MedicalDeviceUserFee/UCM526395.pdf
Notice NOT-NS-17-034 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-309 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The present announcement seeks R01 applications.
Funding Opportunity PAR-17-310 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. The present announcement seeks R21 applications.
Funding Opportunity PAR-17-312 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NINDS Neuroscience Development for Advancing the Careers of a Diverse Research Workforce R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by (1) increasing the pool of current and future Ph.D.-level research scientists from diverse backgrounds underrepresented in biomedical neuroscience research; and (2) facilitating the career advancement/transition of the participants to the next step of their neuroscience careers.
Funding Opportunity RFA-CA-17-027 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to enhance NCIs program for conducting early phase clinical trials in children with cancer, currently supported as the Children's Oncology Group (COG) Phase 1 and Pilot Consortium. The overall goal is to ensure that high priority novel agents can be tested in pediatric patients in a timely manner. Towards this end, applications are solicited for the Pediatric Early Phase Clinical Trials Network (PEP-CTN) to continue the clinical research activities now supported through the COG Phase 1 and Pilot Consortium.
Notice NOT-GM-17-009 from the NIH Guide for Grants and Contracts